Clinical trials: Alopecia, Androgenetic
- Condition Alopecia, Androgenetic
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Mixed Population of Dermal Cells Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0006931)
Evaluate the ability of injections of Ji Gami(TM) CN to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01669746
- Testing
- Autologous cultured mixed population of dermal cells
- Where
- 7 sites in United States
- Volunteers
- 34 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0002012)
To evaluate the ability of injections of Ji Gami(TM) and Ji Gami(TM) DO to induce hair growth in male and female subjects with hair loss
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451047
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 7 sites in United States
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Androgenetic Alopecia
Assessment of Dutasteride Topical Solution in Male Androgenetic Alopecia
This is a randomized, open-label phase 1/2a study designed to evaluate the pharmacokinetics, pharmacodynamics, and safety of AD-303A (topical formulation) and AD-3031 in male patients with androgenetic alopecia.
- Trial name
- NCT07490327
- Testing
- AD-303A, AD-3031
- Where
- South Korea
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Moogene Medi Co., Ltd
Androgenetic Alopecia
Benefits of a Cosmetic Anti-hair Loss in Males With Hair Loss
Androgenetic alopecia (AGA), also known as androgenic alopecia or male pattern baldness, is the most common type of progressive hair loss.
- Trial name
- NCT06590779
- Testing
- Aminexil® active+ lotion, Finasteride 1mg
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Cosmetique Active International
Androgenetic Alopecia, Hair Loss
Treatment of Androgenetic Alopecia in Females, 9 Beam
The purpose of this study is to evaluate the efficacy of the HairMax LaserComb 2009 9 beam model in promoting hair growth in females diagnosed with androgenetic alopecia when treatment is applied as directed.
- Conditions
- Androgenetic Alopecia, Hair Loss, Female Pattern Baldness
- Trial name
- NCT00981461
- Testing
- HairMax LaserComb, Control Device
- Where
- 5 sites in United States
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Lexington International, LLC
Androgenetic Alopecia
A Study to Evaluate the Effectiveness and Safety of 5 Percent Minoxidil Foam in the Treatment of Male Pattern Hair Loss
The primary purpose of the study is to evaluate the efficacy of a topical 5% minoxidil formulation in males for the treatment of pattern hair loss.
- Trial name
- NCT00151515
- Testing
- minoxidil
- Where
- 15 sites in United States
- Volunteers
- 352 people, healthy volunteers welcome
- Sponsor
- Johnson & Johnson Consumer and Personal Products Worldwide
Androgenetic Alopecia
Safety and Efficacy of Hair Stimulating Complex (HSC) on Hair Growth in Males With Androgenetic Alopecia
The purpose of this study is to evaluate the safety and efficacy in relation to dosing in the administration of Hair Stimulating Complex (HSC) in healthy men.
- Trial name
- HSC Phase I/II (NCT01501617)
- Testing
- Hair Stimulating Complex (HSC), Dulbecco's Modified Eagle Medium, DMEM
- Where
- Philippines
- Volunteers
- 56 people, healthy volunteers welcome
- Sponsor
- Histogen
Androgenetic Alopecia
Evaluation of the Safety, Tolerability and Pharmacokinetics of AH-001 Following Topical Single and Multiple Ascending Dose Administration
The goal of this clinical trial is to assess the safety of the AH-001 drug substance at concentrations of 0.2%, 0.5%, 1%, and 2% in healthy volunteers and male subjects with androgenetic alopecia (AGA).
- Trial name
- NCT06927960
- Where
- United States
- Volunteers
- 64 people, healthy volunteers welcome
- Sponsor
- AnHorn Medicines Co. Ltd.
Androgenetic Alopecia
Photosensitization Study in Androgenetic Alopecia
This study evaluates the potential for induction of photosensitization by P-3074 0.25% finasteride cutaneous solution compared to that of placebo vehicle cutaneous solution and a negative control (0.9% sodium chloride, NaCl)
- Trial name
- NCT02791243
- Testing
- Finasteride 0.25%, Negative Control
- Where
- United Kingdom
- Volunteers
- 58 people, healthy volunteers welcome
- Sponsor
- Polichem S.A.
Androgenetic Alopecia
To Evaluate the Pharmacokinetics and Safety of AD-208
To evaluate pharmacokinetics and safety of AD-208.
- Trial name
- NCT04214808
- Testing
- AD-208, Avodart Soft Capsule 0.5mg
- Where
- South Korea
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Addpharma Inc.
Androgenetic Alopecia (AGA), Chronic Telogen Effluvium
Evaluation of the Dietary Supplement Efficacy Against Hair Loss in Subjects Suffering From Hair Loss
The goal of this study was to learn if dietary supplement in capsules and drinkable works to help hair loss in volunteers with chronic telogen effluvium and androgenetic alopecia and learn about its safety.
- Trial name
- NCT07358403
- Testing
- Dietary supplement capsule use for hair loss, Dietary supplement drinklable use for hair loss
- Where
- Italy
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Lacer S.A.
Androgenic Alopecia
Effect of Pumpkin Seed Oil on Hair Growth in Men With Androgenetic Alopecia
Androgenic alopecia is the most common cause of hair loss in men. Finasteride and minoxidil are available in treatment of androgenetic alopecia, although the former causes decreased libido or ejaculate volume, erectile…
- Trial name
- NCT01852487
- Testing
- 400mg /day during 6 months
- Where
- South Korea
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Dream Plus
Androgenetic Alopecia, Hair Loss
Low Level Light Device as a Primary Therapy for Androgenetic Alopecia
The purpose of this research is to study the safety and effectiveness of a light therapy device for human hair growth. This device, called the GENIX, is a type of cold, or non-heat producing light emitting diode (LED) that will…
- Conditions
- Androgenetic Alopecia, Hair Loss, Thinning Hair, Balding
- Trial name
- NCT04558242
- Testing
- Genix
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- Kiierr International, LLC
Androgenetic Alopecia
Dose-Ranging Efficacy Study of Topical NEOSH101 to Treat Male Pattern Hair Loss
The purpose of this study is to evaluate the safety and efficacy of three doses of topical NEOSH101 applied once-daily (qd) for 16 weeks in men with thinning hair in the top and center of the scalp (Norwood/Hamilton grades III-IV…
- Trial name
- NCT00471510
- Testing
- tetrapeptide aldehyde proteasome inhibitor (NEOSH101)
- Where
- Germany
- Volunteers
- 140 people, healthy volunteers welcome
- Sponsor
- Neosil, Inc.
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004669)
Evaluate the injections of Ji Gami(TM) and Ji Gami(TM) DO, where cells are expanded ex vivo from scalp, to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451177
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 3 sites in United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Alopecia, Androgenetic
A Phase 1 Study of TDM-105795 Topical Solution in Male Subjects With Androgenetic Alopecia (AGA)
Multi-center, fixed volume, randomized, double-blind, vehicle-controlled, parallel group, dose escalation comparison study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).
- Trial name
- AGA (NCT04913519)
- Testing
- TDM-105795
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Technoderma Medicines Inc.
Alopecia, Androgenetic
A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)
Multi-center, randomized, double-blind, vehicle-controlled, parallel group, multi-dose escalation study of TDM-105795 in male subjects, 18 to 55 years old, with Androgenetic Alopecia (AGA).
- Trial name
- NCT05244980
- Testing
- TDM-105795
- Where
- 2 sites in United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Technoderma Medicines Inc.
Androgenetic Alopecia, Male Pattern Baldness
A Study to Evaluate and Compare Injections of Autologous Dermal and Epidermal Cells Into the Balding Scalp of Subjects With Hair Loss (CA-0004541)
The purpose of this study is to evaluate the ability of injections of Ji Gami(TM) N and Ji Gami(TM) NDO to induce hair growth in male and female subjects with hair loss.
- Conditions
- Androgenetic Alopecia, Male Pattern Baldness, Female Pattern Baldness
- Trial name
- NCT01451138
- Testing
- Autologous cultured dermal and epidermal cells
- Where
- 4 sites in United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Aderans Research Institute
Female Pattern Baldness, Alopecia, Androgenetic
Hairstetics™ Anchoring System in Female Pattern Hair Loss (HAS-FPHL)
The aim of the study is to provide evidence of safety and preliminary performance of the Hairstetics™ anchoring system in female subjects affected with androgenetic alopecia (female pattern hair loss; (FPHL)).
- Trial name
- HAS-FPHL (NCT02316418)
- Testing
- Hairstetics™ anchoring system
- Where
- India
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- Hairstetics
Androgenetic Alopecia
Safety, Pharmacokinetics and Efficacy of PP405 in Adults With AGA
The study is a two part study, designed to validate safety results from the Phase 1 PP405-001 trial while also characterizing longer term safety and PK.
- Trial name
- NCT06393452
- Testing
- PP405 0.05% Topical Gel, Topical Vehicle Gel
- Where
- 8 sites in United States
- Volunteers
- 78 people, healthy volunteers welcome
- Sponsor
- Pelage Pharmaceuticals, Inc.